Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] DS-8201

americanpharmaceuticalreviewJanuary 15, 2019

Tag: Daiichi Sankyo , [Fam-] DS-8201 , breast cancers , hormone receptor

PharmaSources Customer Service